Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Signs MOU to Mine High Grade Zone 2 at Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human... see more

Recent & Breaking News (NYSE:MRK)

New Data from Merck’s Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting

Business Wire May 16, 2018

LYNPARZA® (olaparib) Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer

Business Wire May 8, 2018

Moderna and Merck Expand mRNA Cancer Vaccines Collaboration

Business Wire May 3, 2018

Merck Provides Update on KEYNOTE-407 Trial

Business Wire May 3, 2018

Apple Results, Fed Decision, Jobs Report In Focus; Merck, Pfizer Reports Mixed

Benzinga.com  May 1, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  May 1, 2018

Merck Announces First-Quarter 2018 Financial Results

Business Wire May 1, 2018

Merck & Co., Inc. to Host Earnings Call

Accesswire May 1, 2018

15 Stocks To Watch For May 1, 2018

Benzinga.com  May 1, 2018

The Week Ahead: Tesla And Apple Earnings, Dropbox Quiet Period Expires, Fed Rate Decision And More

Benzinga.com  April 30, 2018

Upcoming Earnings: Tech Giant Apple Reports After Tuesday's Close

Benzinga.com  April 30, 2018

Busy Week Begins With McDonald's Beating Estimates; Fed Meeting, Jobs Data Loom

Benzinga.com  April 30, 2018

FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as First-Line Treatment of Metastatic Nonsquamous NSCLC

Business Wire April 30, 2018

Upcoming Earnings: McDonald's Reports On Monday As It Continues On New Growth Plan

Benzinga.com  April 27, 2018

European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial

Business Wire April 23, 2018

Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine

Business Wire April 17, 2018

Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study

Business Wire April 16, 2018

Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

Business Wire April 15, 2018

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma

Business Wire April 15, 2018

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Benzinga.com  April 13, 2018
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested